News & Insights
Stay Informed With Our Latest Updates
Explore our comprehensive collection of news and in-depth insights spanning practice areas, industries, and regions.
Firm News February 4, 2026
Advised BioCryst Pharmaceuticals on $400 Million Debt Financing for Acquisition of Astria Therapeutics
Gibson Dunn represented BioCryst Pharmaceuticals, Inc. in connection with a $400 million senior secured term loan facility to finance the acquisition of Astria Therapeutics, Inc.
Firm News February 4, 2026
Gibson Dunn Represents Petco on $600 Million Bond Financing and $900 Million Term Loan Refinancing
Gibson Dunn represented Petco Health and Wellness Company, Inc. in a private placement offering of $600 million in aggregate principal amount of their 8.250% senior secured notes due 2031.
Firm News February 4, 2026
Gibson Dunn Represents JPMorgan in Refinancing of Garda World Security’s $2.35 Billion Term Loan Facility
Gibson Dunn represented JPMorgan Chase Bank, NA., in connection with the Fifteenth Amendment to its Credit Agreement with Garda World Security Corporation, to (i) increase its term loan by an aggregate principal amount of approximately $63 million to $2.35 billion; and (ii) to reprice and reduce interest rates by 0.25% with respect to the Term Loan and by 0.75% with respect to the revolving credit facility.
Firm News January 12, 2026
Gibson Dunn Represented Arrowhead Pharmaceuticals on Concurrent Public Offerings of Convertible Notes, Common Stock, and Pre-Funded Warrants and Related Capped Call Transactions
Gibson Dunn represented Arrowhead Pharmaceuticals, Inc. on concurrent public offerings of convertible notes, common stock, and pre-funded warrants to purchase common stock for aggregate gross proceeds of $930 million to Arrowhead and capped call transactions relating to the convertible notes.
Firm News December 3, 2025
Gibson Dunn Represented Mauser Packaging Solutions on $3.9 Billion Notes Exchange, $1 Billion Term Loan Financing, ABL Credit Facility Maturity Extension, and Cash Flow Revolver Maturity Extension
Gibson Dunn represented Mauser Packaging Solutions in an exchange offer of $2.6 billion in aggregate principal amount of their outstanding 7.875% Senior First Lien Notes due 2027 for newly issued 7.875% Senior First Lien Notes due 2030 and $1.3 billion in aggregate principal amount of their outstanding 9.25% Senior Secured Second Lien Notes due 2027 for newly issued 9.25% Senior Secured Second Lien Notes due 2030.
Firm News October 7, 2025
Gibson Dunn Represented JPMorgan in Landmark Financing of 3G Capital’s $9.4 Billion Skechers Acquisition
Gibson Dunn advised JPMorgan and the other arrangers and lenders on Beach Acquisition Bidco, LLC’s $4.405 billion credit facilities, comprising a $1.555 billion term loan B facility, a €1.25 billion term loan B facility, and a $1.6 billion multicurrency revolving credit facility, to finance, in part, the approximately $9.4 billion acquisition of Skechers U.S.A., Inc. by 3G Capital
Firm News August 11, 2025
Gibson Dunn Advises Arrowhead Pharmaceuticals on Asset Purchase Agreement Between Sanofi and Visirna Therapeutics
Gibson Dunn is advising Arrowhead Pharmaceuticals on an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead. Under the terms, Sanofi will acquire rights to develop and commercialize investigational plozasiran in Greater China
Firm News July 24, 2025
Gibson Dunn Represented J.P. Morgan in a $300 Million Revolving Credit Facility to Borrower Teladoc Health, Inc.
Gibson Dunn represented J.P. Morgan as lead arranger, administrative agent, and a lender in connection with a $300 million revolving credit facility to Teladoc Health, Inc., as borrower under the credit facility.